BriaCell Therapeutics Corp.

BriaCell Therapeutics Corp. is a clinical-stage biotechnology company focused on developing novel immunotherapies for cancer treatment. The company's core business model revolves around advancing its pipeline of immunotherapy candidates through clinical trials with the ultimate goal of commercialization. Revenue generation is currently absent, as the company is in the development stage, and its financial stability is dependent on securing additional financing. The primary customer segments, once products are approved, would be patients with advanced metastatic cancers, particularly breast and prostate cancer, who have limited alternative treatment options. The company relies heavily on third-party contract manufacturers and clinical research organizations for its operations, indicating a capital-light approach to development.

The company's lead product candidate is Bria-IMT™, a whole-cell immunotherapy for metastatic breast cancer. This therapy is designed to secrete GM-CSF, which stimulates dendritic cells to activate T cells to recognize and destroy tumor cells. Bria-IMT™ is currently in a pivotal Phase 3 study in combination with an immune checkpoint inhibitor (Retifanlimab) for metastatic breast cancer, which has received Fast Track Designation from the FDA. The Phase 3 study is expected to enroll 177 patients in the Bria-IMT™ combination arm and 177 patients in the physician's choice arm, with an additional 50 patients in the Bria-IMT™ regimen alone arm for further information gathering. The primary endpoint for the pivotal study is overall survival, with an interim evaluation for efficacy at 144 mortalities. Positive results from a Phase 1/2 study of Bria-IMT™ in combination with immune checkpoint inhibitors showed a median overall survival of 13.4 months ¹ for all patients, and 16.5 months ² for patients treated since 2022 with the Phase 3 formulation. In HR+ metastatic breast cancer patients, the median overall survival was 17.3 months ³, exceeding TRODELVY® (14.4 months ⁴) and chemotherapy (11.3 months ⁵). For TNBC patients, Bria-IMT™ plus CPI showed a median overall survival of 13.9 months ⁶, compared to TRODELVY® (11.8 months ⁷) and chemotherapy (6.9 months ⁸). The intracranial overall response rate (iORR) for patients with intracranial metastatic disease was 71% ⁹.

Another significant product in the pipeline is Bria-OTS™, a personalized off-the-shelf immunotherapy, also known as Bria-BRES™, for metastatic breast cancer. A Phase 1/2 study of Bria-OTS™ is ongoing (NCT06471673), with the first patient treated with single-agent Bria-OTS™ demonstrating complete resolution of a lung metastasis. Bria-OTS™ is engineered to express 15 unique HLA types through 4 independent cell lines, aiming to provide matched treatment to over 99% ¹⁰ of patients. The company also has an enhanced version, Bria-OTS+™, in development for prostate cancer (Bria-PROS+™), lung cancer (Bria-LUNG+™), and melanoma (Bria-MEL+™), as well as breast cancer (Bria-BRES+™). In September 2024, BriaCell received positive feedback from its Pre-IND meeting with the FDA for Bria-PROS+™ for prostate cancer, with the FDA waiving requirements for animal toxicology and pharmacokinetic studies.

BriaPro Therapeutics Corp., a majority-owned subsidiary of BriaCell, is developing high-affinity antibodies against B7-H3, an immune checkpoint molecule, to be incorporated into its proprietary Bria-TILsRx™ platform. This platform is designed to activate tumor-infiltrating lymphocytes within the tumor microenvironment and utilize multivalent technology for simultaneous engagement of multiple cancer-associated and immune pathway targets. BriaPro also has a small molecule program focused on Protein Kinase C delta (PKCδ) inhibitors.

For the fiscal year ended July 31, 2025, BriaCell reported a net loss of $26,311,867 ¹¹, a significant increase from the net loss of $4,791,466 ¹² in the fiscal year ended July 31, 2024. The accumulated deficit as of July 31, 2025, was $111,755,564 ¹³, compared to $85,443,697 ¹⁴ as of July 31, 2024. Total operating expenses for 2025 were $27,204,803 ¹⁵, down from $33,330,076 ¹⁶ in 2024. Research and development expenses decreased from $27,177,807 ¹⁷ in 2024 to $21,270,678 ¹⁸ in 2025. General and administrative expenses were $5,934,125 ¹⁹ in 2025, compared to $6,152,269 ²⁰ in 2024. The company had cash and cash equivalents of $10,493,808 ²¹ and short-term investments of $7,372,473 ²² as of July 31, 2025, resulting in a positive working capital of $15,948,588 ²³, a notable improvement from a negative working capital of $3,807,303 ²⁴ in 2024. Total current liabilities were $3,977,988 ²⁵ in 2025, down from $7,461,157 ²⁶ in 2024. Diluted EPS was $(62.19) ²⁷ for 2025, compared to $(43.68) ²⁸ for 2024.

The decrease in research and development costs was primarily due to lower clinical trial sites and investigational drug costs, which decreased from $20,885,903 ²⁹ in 2024 to $14,765,112 ³⁰ in 2025, reflecting the conclusion of the Bria-IMT™ Phase 1/2a trial and optimization of expenditures for the pivotal Phase 3 trial. Wages and salaries within R&D increased from $4,567,307 ³¹ in 2024 to $5,356,806 ³² in 2025. Clinical trial expenses for the Bria-IMT™ Pivotal Phase 3 study increased from $11,594,463 ³³ in 2024 to $13,511,235 ³⁴ in 2025. Bria-OTS™ Phase 1/2a costs totaled $428,233 ³⁵ in 2025, as the trial commenced in August 2024. The significant increase in net loss was primarily driven by a smaller gain on the fair value of the warrant liability, which was $758,364 ³⁶ in 2025 compared to $28,242,472 ³⁷ in 2024.

During the fiscal year ended July 31, 2025, BriaCell completed several financings, raising approximately $50.9 million ³⁸ in gross proceeds. The company announced that its pivotal Phase 3 clinical study for Bria-IMT™ has consented over 100 ³⁹ and enrolled over 75 ⁴⁰ patients as of April 22, 2025. The Data Safety Monitoring Board (DSMB) completed its first, second, and third reviews of safety events in the Phase 3 study, recommending continuation with no safety concerns. On April 30, 2025, BriaCell reported "Late-Breaker" Phase 3 data at AACR 2025, identifying potential predictive biomarkers for treatment response, including positive delayed-type hypersensitivity (DTH) (p = 0.001 ⁴¹) and a favorable Neutrophil-to-Lymphocyte Ratio (NLR) (p = 0.02 ⁴²) linked to longer progression-free survival. The company also announced a clinical supply agreement with BeiGene for the Bria-OTS™ First in Human Study on May 28, 2024, to evaluate Bria-OTS™ in combination with anti-PD-1 antibody tislelizumab. On February 3, 2025, a clinical response, including resolution of a lung metastasis, was observed in the first metastatic breast cancer patient treated with Bria-OTS™ as a single agent, which was confirmed at 4 months and maintained at 6 months.

BriaCell anticipates reporting top-line data for its pivotal Phase 3 Bria-IMT™ study as early as H1-2026. The FDA has agreed that improvement in overall survival in the Bria-IMT™ combination arm compared to the physician's choice of treatment arm will be the primary endpoint of the study. The study will have an interim evaluation for efficacy at 144 events (mortalities). If the hazard ratio (HR) is ≤ 0.6 ⁴³, BriaCell will submit a Biologics Licensing Application (BLA). If the HR is > 0.6 ⁴⁴, the study will continue to completion with an HR target of 0.7 ⁴⁵. Either of these outcomes could lead to full approval of the Bria-IMT™ CPI combination regimen in advanced metastatic breast cancer.

The company's growth areas include the continued development of Bria-OTS™ and its advanced form, Bria-OTS+™, as a platform technology for personalized off-the-shelf immunotherapies for various cancer types. Bria-OTS™ is engineered to express 15 unique HLA types through 4 independent cell lines, aiming to provide matched treatment to greater than 99% ⁴⁶ of patients. The company has secured numerous US and international patents for Bria-OTS™. IND filings for Bria-OTS+™ immunotherapy cell lines for prostate cancer (Bria-PROS+™), lung cancer (Bria-LUNG+™), and melanoma (Bria-MEL+™) are anticipated starting in late 2025 or early 2026. BriaCell received a Small Business Innovation Research (SBIR) grant of approximately US$2.05 million ⁴⁷ from the U.S. National Cancer Institute (NCI) to advance the clinical development of Bria-PROS+™ for prostate cancer, which will fund manufacturing of clinical supply and support the upcoming Phase 1/2a clinical trial.

Operationally, BriaCell expects operating expenses and staffing levels to increase in the future as it advances its clinical programs, scales its operations, and undertakes activities necessary to support potential commercialization. The company will need to attract, retain, train, and motivate additional qualified personnel and continue developing and improving its operational, financial, and management information systems. Managing this growth will also require effective management of multiple, interdependent relationships with third-party contract research organizations, contract manufacturers, clinical investigators, regulatory authorities, academic collaborators, and suppliers. The company has a month-to-month lease arrangement for office and lab space in Philadelphia, Pennsylvania, costing approximately $43,000 ⁴⁸ per month as of September 1, 2025.

BriaCell's capital allocation strategy includes funding ongoing clinical trials and advancing its pipeline programs. The company anticipates that additional capital will be required to complete its current research and development programs, including future research, additional pre-clinical and toxicology studies, and manufacturing initiatives. During the year ended July 31, 2025, the company raised $50.9 million ⁴⁹ in gross proceeds from equity financings. The company's investment policy and strategy are focused on preservation of capital and supporting liquidity requirements.

Management explicitly flagged several structural headwinds and execution risks. The company has an unproven market for its product candidates and is a pre-revenue clinical-stage company, meaning its ability to generate revenues and achieve profitability depends on successfully completing product development, obtaining market approval, and generating significant revenues. There is substantial doubt about the company's ability to continue as a going concern, as it has incurred significant losses, including net losses of $26,311,867 ⁵⁰ and $4,791,466 ⁵¹ in fiscal years 2025 and 2024, respectively, and an accumulated deficit of $111,755,564 ⁵² as of July 31, 2025. The company's continuation as a going concern is dependent on generating positive cash flows from operations and securing additional equity and/or debt financing.

BriaCell faces significant risks, including the inherent uncertainty of clinical trials where pre-clinical and early-stage results may not predict future outcomes in larger, more diverse patient populations or commercial settings. The company is heavily reliant on third-parties for manufacturing, pharmaceutical development, and marketing, and any failure in these contractual duties or regulatory obligations could delay or terminate clinical trials and commercialization efforts. Intellectual property protection is crucial, but patents provide limited protection, and the company is susceptible to intellectual property suits, which can be expensive and divert management's attention. Changes in legislation and regulations, particularly regarding drug pricing, reimbursement, and data privacy (such as HIPAA and the Data Protection Directive in the E.U.), could adversely affect revenue and profitability, and non-compliance could lead to significant penalties. There is substantial doubt about the company's ability to continue as a going concern, given its history of significant losses, including a net loss of $26,311,867 ⁵³ in fiscal year 2025 and an accumulated deficit of $111,755,564 ⁵⁴ as of July 31, 2025, and negative cash flows from operating activities of $28,170,520 ⁵⁵ in 2025. The company's ability to raise additional capital on acceptable terms is not assured, and failure to do so could lead to delays or discontinuation of product development. The company is highly dependent on key personnel, and the loss of their services could materially adversely affect the business. Data security breaches and cyber-attacks pose risks of liability, negative publicity, and operational disruptions. International operations expose the company to country-specific taxation policies, governmental controls, trade restrictions, and complexities in collecting receivables. The company's common shares are subject to Nasdaq listing requirements, and failure to comply could result in delisting, impacting liquidity and market price. Global economic uncertainty and financial market volatility, including geopolitical instability and conflicts, could make it more difficult to access financing and disrupt supply chains, leading to increased costs and delays. Inflation also has the potential to adversely affect the business by increasing overall cost structure, particularly labor and materials.

Management's message to shareholders conveys a tone of cautious optimism, emphasizing the significant progress in advancing its immunotherapy pipeline despite the financial challenges inherent in a clinical-stage biotechnology company. They highlight the pivotal Phase 3 study of Bria-IMT™ in metastatic breast cancer, noting its Fast Track Designation by the FDA and the potential for full approval following positive completion. Management is focused on optimizing expenditures for this trial and has reported benchmark-beating patient survival and clinical benefit in earlier studies. They also underscore the advancement of Bria-OTS™ as a personalized off-the-shelf immunotherapy, citing a clinical response in the first patient treated and positive feedback from the FDA for Bria-PROS+™. Strategic priorities include the successful completion of the Bria-IMT™ pivotal study, with top-line data anticipated as early as H1-2026, and the continued development and anticipated IND filings for Bria-OTS+™ immunotherapy cell lines starting in late 2025 or early 2026. Management also emphasizes the importance of securing additional capital to fund ongoing research and development programs, acknowledging the substantial doubt about the company's ability to continue as a going concern due to recurring losses, including a net loss of $26,311,867 ⁵⁶ in 2025 and an accumulated deficit of $111,755,564 ⁵⁷. They are actively pursuing strategies to mitigate these risks, focusing on transitioning towards revenue generation and expanding the customer base, while also reducing expenditure on non-core activities.